Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28024008 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL9816467 | 1.00 | — | — | |
| SCHEMBL28023941 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7370616 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL832715 | 0.97 | — | — | |
| SCHEMBL1459306 | 0.87 | — | — | |
| SCHEMBL2568120 | 0.83 | — | — | |
| SCHEMBL20494560 | 0.83 | — | — | |
| SCHEMBL2565575 | 0.83 | — | — | |
| Butyl Alcohol SCHEMBL10564523 | 0.82 | LMNA (0.55) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114316102-A | Alkoxy magnesium carrier, polyethylene catalyst and preparation method thereof | 北京吉海川科技发展有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| EP-0611756-A2 | Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
| WO-1993017025-A1 | 3-SUBSTITUTED IMIDAZO(1,5-A)QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY | THE UPJOHN COMPANY (US) | 1993-09-02 | — | — | WO | disclosed |
| WO-1993010097-A1 | NITRO COMPOUNDS HAVING VASODILATOR ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-27 | — | — | WO | disclosed |
| US-5043459-A | Saccharoascorbic acid derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0381472-A1 | Saccharoascorbic acid derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-08-08 | — | — | EP | disclosed |
| US-4892873-A | MUSCLE RELAXANTS, ANTIEPILEPTIC, AN XIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4843082-A | 1,2,3,4-tetrahydro-8-quinolinol derivatives and anti-allergic use thereof | E. R. SQUIBB & SONS, INC. (US) | 1989-06-27 | — | — | US | disclosed |
| US-4767765-A | ANXIOLYTIC OR ANTIEPILEPTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0223974-A1 | N-Substituted-N-[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-phenyl]alkanamides, carbamates and ureas | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
| US-4654343-A | USEFUL AS ANXIOLYTIC OR ANTIEPILEPTIC AGENTS AS WELL AS SEDATIVE-HYPNOTIC AND SKELETAL MUSCLE RELAXANT AGENTS | AMERICAN CYANAMID COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | LMNA 2509/4885ALDH1A1 1286/4885HSD17B10 887/4885 |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FGFR3 | LMNA 4818/4885ALDH1A1 1477/4885HSD17B10 3225/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | LMNA 1865/4885ALDH1A1 827/4885HSD17B10 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.